4 - TRANSENTERIX, INC. (0000876378) (Issuer)

4 - TRANSENTERIX, INC. (0000876378) (Issuer)

8-K - ASENSUS SURGICAL, INC. (0000876378) (Filer)

10-K - ASENSUS SURGICAL, INC. (0000876378) (Filer)

8-K - ASENSUS SURGICAL, INC. (0000876378) (Filer)

8-K - ASENSUS SURGICAL, INC. (0000876378) (Filer)

8-K - TRANSENTERIX, INC. (0000876378) (Filer)

8-K - TRANSENTERIX, INC. (0000876378) (Filer)

424B5 - TRANSENTERIX, INC. (0000876378) (Filer)

8-K - TRANSENTERIX, INC. (0000876378) (Filer)

SC 13G/A - TRANSENTERIX, INC. (0000876378) (Subject)

FWP - TRANSENTERIX, INC. (0000876378) (Subject)

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Asensus Surgical, Inc. (NYSE American: TRXC) (formerly TransEnterix, Inc.), a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™, announced today that it plans to release fourth quarter and fiscal year 2020 financial and operating results after the market closes on Thursday, March 11, 2021. The Company will host a conference call to discuss these results starting at 4:30 p.m. ET the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial 1-855-327-6837 for domestic callers and 1-631-891-4304

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Asensus Surgical, Inc. (formerly TransEnterix, Inc.) (NYSE American: TRXC) , a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™, today announced the Company has received an additional FDA clearance for the Senhance Surgical System which allows for indication expansion in general surgery in the United States. Asensus Surgical's technology platform, Senhance® Surgical System, is the first of its kind digital laparoscopic platform that leverages augmented intelligence to provide unmatched performance and patient outcomes through machine learning.

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Asensus Surgical, Inc. (NYSE American: TRXC) (formerly TransEnterix, Inc.), a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery, announced today that Anthony Fernando, President and Chief Executive Officer, and Shameze Rampertab, Executive Vice President and Chief Financial Officer, will participate in the H.C. Wainwright Virtual Global Life Sciences Conference taking place March 9 and March 10, 2021. The Company’s presentation will be available for on-demand beginning Tuesday, March 9, 2021 at 7:00 am ET. The on-demand conference presentation wil

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that it will change its corporate name to Asensus Surgical, Inc. The name change reflects the company's broader vision of shaping the future of surgery by integrating computer vision and machine learning with surgical robotics. While the company name change is effective today, the company's stock will begin trading under the new ticker symbol, NYSE American: ASXC, and name, Asensus Surgical, Inc., at the open of trading on March 5, 2021. Asensus S

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced the Company has agreed to partner with the Amsterdam Skills Centre (ASC) in the Netherlands for surgical training. This site will serve surgeons and staff throughout Europe with basic and advanced training on the Senhance® Surgical System. The ASC will also provide TransEnterix with a world-class facility to engage European surgeons in technology and clinical development studies. “As TransEnterix continues to expand our footprint and adoption in E

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that it will host a virtual Investor Day on February 23, 2021, beginning at 11:00am Eastern Time. “We are excited to provide an update on Senhance, including a deep dive into the technology and how we are positioning the system in Digital Laparoscopy. In addition, we will be providing updates on our corporate strategy and market opportunity,” said Anthony Fernando, President and Chief Executive Officer of TransEnterix. “The company made tremendous

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced the closing of its previously announced underwritten public offering of its common stock. Including the full exercise of the underwriter’s option to purchase additional shares, the Company issued 26,545,832 shares at a public offering price of $3.00 per share. The aggregate gross proceeds from this offering is approximately $79.64 million, before deducting underwriting discounts and commissions and offering expenses. H.C. Wainwright & Co. acted as t

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--TransEnterix, Inc. (NYSE American: TRXC) (“TransEnterix” or the “Company”), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that, due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commitment basis 23,083,333 shares of common stock of the Company at a public offering price of $3.00 per share, less underwriting discounts and commissions. The Company also has granted the underwriter a 30-day option to purchase up to an additional 3,462,499 shares of common stock at the

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--TransEnterix, Inc. (NYSE American: TRXC) (“TransEnterix” or the “Company”), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co. under which the underwriter has agreed to purchase on a firm commitment basis 8,333,334 shares of common stock of the Company at a public offering price of $3.00 per share, less underwriting discounts and commissions. The Company also has granted the underwriter a 30-day option to purchase up to an additional 1,250,000 shares of common sto

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced the Company received CE Mark approval for the Intelligent Surgical UnitTM (ISUTM) that enables machine vision capabilities on the SenhanceⓇ Surgical System. This approval will provide Senhance digital laparoscopic programs in Europe access to this new technology, ushering them to the forefront of surgical innovation utilizing augmented intelligence. “Augmented intelligence powered by machine vision will be one of the primary drivers in transformin

SC 13G/A - TRANSENTERIX, INC. (0000876378) (Subject)